Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Capricor Therapeutics is set to present updates on its exosome platform technology at the ASGCT 27th Annual Meeting, showcasing a potential exosome-based approach for treating arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease. The preclinical findings demonstrate the therapeutic potential of Capricor's StealthX™ exosome platform technology in delivering enzyme-replacement therapies. The company aims to leverage partnership opportunities to advance its exosome platform for therapeutic and vaccine development.
Capricor Therapeutics (CAPR) is set to present at various upcoming scientific and medical conferences, showcasing their transformative cell and exosome-based therapeutics for rare diseases. The company will be discussing potential applications for the treatment of rare diseases like Arginase-1 Deficiency and Duchenne Muscular Dystrophy. The presentations will cover advancements in targeted cargo delivery and disease modification in later-stage patients. These conferences provide a platform for Capricor to share their innovative research and progress in the biotechnology sector.
Capricor Therapeutics, a biotechnology company focusing on cell and exosome-based therapeutics for rare diseases, will announce its first quarter 2024 financial results on May 13, 2024. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to provide a corporate update.
FAQ
What is the current stock price of Capricor Therapeutics (CAPR)?
What is the market cap of Capricor Therapeutics (CAPR)?
